How to Start a TRT Telehealth Business in 2026 (and Plan for the DEA Deadline)

Checked October 18, 2026. Prices are entry prices from the Telehealth Match database (our sister comparison site).

The medications

• Testosterone (injections, gels, oral undecanoate, pellets) is Schedule III (21 CFR 1308.13). In February 2025 FDA removed the boxed-warning language on increased cardiovascular risk after the TRAVERSE trial and added blood-pressure warnings. The labels still limit use to low testosterone with an associated medical condition, not "age-related" decline (FDA).
• Enclomiphene isn't FDA-approved. FDA told its compounding advisory committee in 2022 that it proposed not adding it to the 503A bulks list (FDA). Some pharmacies compound it as a component of clomiphene: a grey zone. It isn't controlled, which is why many brands lead with it.
• Clomiphene is approved for women; use in men is off-label.

The DEA deadline

The Ryan Haight Act requires an in-person evaluation before controlled substances are prescribed online. The DEA's fourth temporary extension waives that through December 31, 2026 (Federal Register). A permanent special-registration rule was reported to be under White House review in fall 2026, and no further extension had been announced as of October 18. Some states are already stricter than the DEA. Full detail in our structure guide.

Plan for January 2027:

• a way to give new patients an in-person evaluation (partner clinics, lab sites with clinicians, or local providers);
• non-controlled options such as enclomiphene where clinically appropriate and your counsel is comfortable;
• existing patients' prescriptions reviewed against whatever rule is in force.

Labs: follow the guideline

The AUA guideline (AUA):

• Diagnosis: total testosterone below 300 ng/dL on two separate early-morning tests, plus symptoms or signs.
• Baseline: hematocrit, PSA in men over 40, LH when testosterone is low (prolactin if LH is low), estradiol if there's breast enlargement.
• Monitoring: testosterone 2–4 weeks after starting, then every 6–12 months; hematocrit every 6–12 months, keeping it below 54%.

The Endocrine Society's guideline is similar and also holds therapy when hematocrit is above 54% (JCEM, 2018). Every TRT brand in the database sells or requires labs, so build them into the price and the flow.

What brands charge

Entry prices often require a 6- or 12-month prepay, so compare on the monthly price a patient actually pays. Anastrozole, a common add-on, costs $2.49 for 30 tablets at Cost Plus Drugs. Testosterone itself isn't sold there, and no reputable public wholesale price for it exists, so get pharmacy quotes.

Retention

Testosterone retention is weak in real-world data. Of 121,852 men who started testosterone cypionate injections, only 8.2% were still on it at 12 months (Androgens, 2022). That's insurance-era data, not cash-pay telehealth, but the lesson stands. Proactive follow-up, lab-driven dose adjustment and clear expectations at intake are what keep patients.

Claim and ad rules

• Keep claims to diagnosed hypogonadism. "Anti-aging," "more energy for every man" and "age-related low T" conflict with the label's limitation of use.
• Don't describe enclomiphene or any compounded product as FDA-approved or "the same as" an approved drug. FDA's compounded-drug letters apply across verticals (503A vs 503B).
• Google and Meta require LegitScript plus platform authorization for prescription ads, and Google bans hCG promoted with anabolic steroids (Google, our LegitScript guide).

Launch checklist

1. Pick a clinician network that prescribes controlled substances. Not all do: MD Integrations, for example, doesn't (partners compared).
2. Build guideline labs into intake and follow-up.
3. Decide your 2027 plan for new patients before you spend on acquisition.
4. Price with labs and prepay terms shown clearly.
5. Write claims to the label and get LegitScript before ads.

---